|
|
Article: American Red Cross signs agreement to supply Viragen with human leukocytes for up to 15 years.
- Article from:
- Transplant News
- Article date:
- September 30, 1998
CopyrightCOPYRIGHT 1998 Transplant Communications, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Viragen, Inc., and Viragen USA, Viragen's wholly owned subsidiary, Plantation, FL, announced they have entered into an agreement with The American Red Cross (ARC), Washington, D.C., to obtain ARC's human leukocytes (white blood cells) for up to 15 years for the production of therapeutic drugs, including natural interferon. Viargen uses white blood cells as the source material for the manufacture of Omniferon, its proprietary, multi-subtype, highly purified natural alpha interferon drug currently in preclinical studies. The company says it expects to complete such studies by the end ...